Rac1b inhibitor

Rac1b inhibitor is a small molecule antineoplastic agent under development by Revere Pharmaceuticals for the treatment of solid tumors. It acts as an inhibitor of the Rac1 GTP binding protein, specifically targeting the Rac1b isoform, which is implicated in cancer cell proliferation, migration, and survival. By inhibiting Rac1/Rac1b activity, this drug aims to disrupt key signaling pathways involved in tumor growth and metastasis. As of March 2025, it remains in preclinical development for solid tumors[1][6]. The mechanism involves blocking GDP/GTP exchange on Rac proteins and interfering with their interaction with guanine nucleotide exchange factors (GEFs), thereby reducing downstream oncogenic signaling[3][4].